Monday, 14 March 2011

First oral treatment for people with multiple sclerosis approved in Canada

Source Canada NewsWire:

Shown to significantly reduce relapses and slow disease progression

DORVAL, QC, March 10 /CNW/ - Novartis Pharmaceuticals Canada Inc. announced today that its new MS treatment, Gilenya™ (fingolimod), has received Notice of Compliance in Canada. Gilenya™ (fingolimod) is the first disease modifying oral therapy developed for the relapsing-remitting form of multiple sclerosis (MS) which is the most common type of the disease in adults.